NEW YORK (GenomeWeb News) – Abbott today reported that its third quarter revenues increased 2 percent year over year, with a decline in pharmaceuticals sales offset by gains in its diagnostics business.

Overall, the firm reported sales of $5.37 billion, up from $5.27 million for the third quarter of 2012. Abbott's Nutrition and Medical Devices businesses both reported 2 percent revenue gains year over year, while Pharmaceuticals fell 3 percent. Its Diagnostics business, however, reported sales growth of 8 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.